Logo

Celltrion Reports Results of Herzuma (biosimilar, rastuzumab) + Gedatolisib in P-II Study for the Treatment of Metastatic Breast Cancer

Share this
Celltrion Reports Results of Herzuma (biosimilar, rastuzumab) + Gedatolisib in P-II Study for the Treatment of Metastatic Breast Cancer

Celltrion Reports Results of Herzuma (biosimilar, rastuzumab) + Gedatolisib in P-II Study for the Treatment of Metastatic Breast Cancer

Shots:

  • The P-II study evaluates Herzuma (a trastuzumab biosimilar) + gedatolisib in patients with HER2–positive mBC with a PIK3CA aberration whose cancers had progressed after multiple lines of therapy
  • The results showed a 58.8% ORR with manageable toxicity, DCR was 82.4%, m-PFS was 5.9mos. Additionally, 3 patients had progressive disease, 4 with SD, and 10 showed PR. The results were presented at SABCS 2021
  • Trastuzumab is a mAb that targets HER2 & binds to the HER2/neu receptor and reduces HER2 expression along with the growth of blood vessels to support tumor growth while Gedatolisib targets the mTOR/PIK3 signaling pathway

Ref: Center for Biosimilars | Image: The Korea Economic Daily

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions